片頭痛の予防治療におけるフレマネズマブ（TEV-48125）の皮下投与の有効性と安全性

基本情報

NCT ID

NCT02638103

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

1,890

治験依頼者名

Teva Branded Pharmaceutical Products R&D, Inc.

概要

A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous (SC) administration of TEV-48125 in adult participants with chronic migraine (CM) or episodic migraine (EM). Participants with CM or EM who complete the pivotal efficacy studies of TEV-48125 (TV48125-CNS-30049 \[NCT02621931\] and TV48125-CNS-30050 \[NCT02629861\]) and agree to participate in this study; and new participants meeting eligibility criteria (not rolling over from pivotal studies), will be enrolled in this study.

対象疾患

介入

依頼者（Sponsor）

実施施設 (13)